Dashboard
Manage Tickers

ATRA Atara Biotherapeutics, Inc.


$ 16.20 $ -1.16 (-7.35 %)    

Wednesday, 22-Oct-2025 16:09:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 15.71
$ 14.11 x 1
$ 16.94 x 2
-- - --
$ 5.01 - $ 18.71
45,056
na
102.75M
$ 1.55
$ 17.73
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/17/2025 21:07:13

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals
4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

atara-biotherapeutics-greg-ciongoli-to-assume-the-role-of-chair-of-the-board-of-directors
Atara Biotherapeutics' Greg Ciongoli To As...
09/03/2025 22:03:16

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

atara-biotherapeutics-says-co-has-resumed-its-evaluation-of-strategic-options
Atara Biotherapeutics Says Co Has Resumed ...
08/11/2025 20:30:32

atara-biotherapeutics-q2-eps-019-beats-081-estimate-sales-1757m-beat-567m-estimate
Atara Biotherapeutics Q2 EPS $0.19 Beats $...
08/11/2025 20:13:10

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of...

atara-biotherapeutics-says-fda-accepts-filing-of-bla-for-tabelecleucel-indicated-as-monotherapy-for-treatment-of-patients-with-ebv-ptld-who-have-received-at-least-one-prior-therapy
Atara Biotherapeutics Says FDA Accepts Fil...
07/24/2025 12:20:13

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026If Approved, Tab-cel Would Be First Approved Thera...

pierre-fabre-pharma-announces-transfer-of-ind-application-for-tabelecleucel-from-its-partner-atara-biotherapeutics
Pierre Fabre Pharma Announces Transfer Of ...
07/15/2025 12:19:01

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnr...

atara-biotherapeutics-resubmits-tabelecleucel-biologics-license-application
Atara Biotherapeutics Resubmits Tabelecleu...
07/14/2025 12:01:03

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

atara-biotherapeutics-q1-eps-350-beats-198-estimate-sales-9815m-beat-567m-estimate
Atara Biotherapeutics Q1 EPS $3.50 Beats $...
05/15/2025 13:17:07

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of...

atara-biotherapeutics-prices-offering-of-834237-shares-at-661shr-and-pre-funded-warrants-at-66099-per-pre-funded-warrant-share-in-underwritten-registered-direct-offering
Atara Biotherapeutics Prices Offering Of 8...
05/15/2025 12:36:02

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 12:08:25

atara-biotherapeutics-provides-regulatory-updates-on-ebvallo-fda-lifts-clinical-hold-enabling-resumption-of-clinical-trials-fda-has-granted-a-type-a-meeting-to-discuss-path-forward-for-bla
Atara Biotherapeutics Provides Regulatory ...
05/05/2025 21:20:46

FDA lifts clinical hold enabling resumption of clinical trialsFDA has granted a Type A Meeting to discuss path forward for BLAA...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/24/2025 12:06:59

atara-biotherapeutics-transfers-full-manufacturing-responsibility-for-tabelecleucel-to-pierre-fabre-now-entitled-to-receive-up-to-550m-in-additional-potential-milestone-payments-upon-achieving-certain-regulatory-and-commercial-milestones-relating-to-tab-cel-including-up-to-40m-in-potential-regulatory-milestones-in-connection-with-the-approval-by-the-fda-of-a-bla-for-tab-cel
Atara Biotherapeutics Transfers Full Manuf...
04/04/2025 20:36:39

On March 31, 2025, Atara Biotherapeutics, Inc., (the "Company") entered into an Amendment (the "Amendment") to ...

canaccord-genuity-maintains-buy-on-atara-biotherapeutics-maintains-17-price-target
Canaccord Genuity Maintains Buy on Atara B...
03/11/2025 13:08:34

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.

atara-biotherapeutics-q4-2024-gaap-eps-119-beats-358-estimate-sales-32753-miss-19148m-estimate
Atara Biotherapeutics Q4 2024 GAAP EPS $(1...
03/07/2025 21:03:45

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of...

hc-wainwright--co-reiterates-neutral-on-atara-biotherapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
01/28/2025 12:09:30

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

hc-wainwright--co-reiterates-neutral-on-atara-biotherapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
01/22/2025 12:51:22

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

fda-places-clinical-hold-on-atara-biotherapeutics-two-cell-therapy-programs
FDA Places Clinical Hold On Atara Biothera...
01/21/2025 18:11:23

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION